Intracranial Pressure Monitoring Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Intracranial Pressure Monitoring Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Intracranial Pressure Monitoring Devices Market by Technique (Invasive [External Ventricular Drainage (EVD) and Microtransducer ICP Monitoring], and Noninvasive [Transcranial Doppler Ultrasonography, MRI/CT, and Others]), Product Type (Monitors, Probes, Catheters and Kits, and Others), Application (Traumatic Brain Injury, Intracerebral Hemorrhage, Meningitis, and Others), End-User (Hospitals, Homecare, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing instances of neurological disorders and the rising product developmental activities across the globe

The intracranial pressure monitoring devices market was valued at USD 1.55 billion in 2023, growing at a CAGR of 7.60% during the forecast period from 2024 to 2030 to reach USD 2.40 billion by 2030. The intracranial pressure monitoring devices market is experiencing significant growth due to the increasing instances of neurological disorders such as multiple sclerosis and epilepsy, and dementia, coupled with increasing awareness of these disorders, and rising product developmental activities that are acting as major factors contributing to the overall growth of the intracranial pressure monitoring devices market during the forecast period from 2024 to 2030.

Intracranial Pressure Monitoring Devices Market Dynamics:

As per data from the World Health Organization (WHO) (2023), it was reported that over 1.8 million people worldwide are affected by Multiple sclerosis (MS). It impacts various functions including cognitive, emotional, motor, sensory, and visual abilities. It occurs when the immune system mistakenly attacks the brain and spinal cord.

Data from the WHO stated that in 2024, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could have lived seizure-free if they had been properly diagnosed and treated. Additionally, globally, an estimated 5 million people are diagnosed with epilepsy each year. In high-income countries, there were estimated to be 49 per 100,000 people diagnosed with epilepsy each year, whereas in low- and middle-income countries, this figure could be as high as 139 per 100,000.

According to data from the WHO (2023), it stated that more than 55 million people had dementia worldwide, with over 60% living in low- and middle-income countries. Each year, there were nearly 10 million new cases.

Since neurological disorders such as multiple sclerosis, epilepsy, and dementia are growing, there is increasing demand for intracranial pressure monitoring devices. These conditions often lead to complications requiring intracranial pressure assessment for effective management. For instance, intracranial pressure monitoring devices is critical in managing secondary effects in multiple sclerosis, during seizures in epilepsy, and in dementia patients to evaluate intracranial dynamics.

Hence, the interplay of all the above-mentioned factors is expected to drive the intracranial pressure monitoring devices market during the given forecast period from 2024 to 2030.

However, the dearth of skilled specialists for equipment operation and handling, potential risks associated with intracranial pressure monitoring devices, and others may restrict the market growth for the intracranial pressure monitoring devices market.

Intracranial Pressure Monitoring Devices Market Segment Analysis:

Intracranial Pressure Monitoring Devices Market by Technique (Invasive [External Ventricular Drainage (EVD) and Microtransducer ICP Monitoring], and Noninvasive [Transcranial Doppler Ultrasonography, MRI/CT, and Others]), Product Type (Monitors, Probes, Catheters and Kits, and Others), Application (Traumatic Brain Injury, Intracerebral Hemorrhage, Meningitis, and Others), End-User (Hospitals, Homecare, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technique segment of the intracranial pressure monitoring devices market, the external ventricular drainage (EVD) sub-category of invasive intracranial pressure monitoring devices is expected to have a significant revenue share in the year 2023. This is due to the numerous advantages and applications in intracranial pressure monitoring offered by external ventricular drainage devices.

External ventricular drainage devices offer numerous advantages in managing patients with critical neurological conditions. These devices provide real-time monitoring and therapeutic relief of elevated intracranial pressure by draining cerebrospinal fluid from the ventricles. EVDs also allow precise control over fluid drainage, ensuring that the brain’s pressure remains within safe limits, which helps in preventing secondary brain damage.

Additionally, these devices serve as a diagnostic tool by allowing for cerebrospinal sampling, which is essential in identifying infections like meningitis or monitoring for hemorrhagic complications. EVDs are minimally invasive and can be placed in emergency situations, providing immediate therapeutic effects. Their adjustability and precision make them a vital part of neurocritical care, improving both patient outcomes and survival rates when used timely and under appropriate clinical contexts.

Therefore, the widespread uses and various advantages of external ventricular drainage device enhance performance and usability, solidifying a significant impact on the growth of the overall intracranial pressure monitoring devices market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall intracranial pressure monitoring devices market:

Among all the regions, North America is estimated to hold a significant revenue share in the intracranial pressure monitoring devices market. This can be attributed to several factors, including the growing burden of Parkinson's disease, the increasing prevalence of brain injuries caused by trauma, and ongoing product development activities by regulatory authorities supported by the presence of key players in the region that contribute to the growth of the intracranial pressure monitoring devices market in the North America region during the forecast period from 2024 to 2030.

Parkinson's Foundation in 2024 stated that, currently near about one million people in the U.S. are living with Parkinson's disease. This number is projected to increase to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disorder, following Alzheimer's disease. Each year, approximately 90,000 new cases of Parkinson's are diagnosed in the US. The increasing prevalence of Parkinson's disease is significantly enhancing the market for intracranial pressure monitoring devices. As the number of diagnosed patients rises, there is a growing need for effective management of neurological complications, including those related to elevated intracranial pressure.

According to data provided by the Centre for Disease Control and Prevention (2024), in 2021, there were more than 586 traumatic brain injury-related hospitalizations per day in the US. Traumatic brain injuries, caused by head trauma from accidents, falls, or sports injuries, require prompt and accurate diagnosis to assess the extent of brain damage and guide treatment decisions. The increasing incidence of traumatic brain injuries is driving demand for intracranial pressure monitoring devices, as traumatic brain injuries result in significant hospitalizations, the need for precise and timely intracranial pressure assessment becomes critical for effective management and prevention of secondary brain injury.

Various product developmental strategies such as clearances in the region by regulatory authorities in the region play a major role in pushing forward the revenue shares of intracranial pressure monitoring devices in the region. For example, in August 2024, Aesculap, Inc., in partnership with Christoph Miethke GmbH & Co. KG, announced the U.S. Food and Drug Administration (FDA) approval for Breakthrough Device Designation for the M.scio® System. This unique, non-invasive, telemetric pressure measurement system is designed to provide continuous access to long-term, intracranial pressure monitoring of cerebrospinal fluid for the management of hydrocephalus via a permanent, fully implantable sensor.

Moreover, product launches by key market players in the region is further expected to propel the growth of the North America intracranial pressure monitoring devices market.

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the intracranial pressure monitoring devices market during the forecast period from 2024 to 2030.

Intracranial Pressure Monitoring Devices Market key players:

Some of the key market players operating in the intracranial pressure monitoring devices market include ArchiMed Group, RAUMEDIC AG, Integra LifeSciences, Sophysa, Spiegelberg GmbH & Co. KG, Medtronic, IRRAS AB, Luciole Medical AG, Saeum Meditec, Recorders & Medicare Systems P Ltd., Shenzhen Delica Medical Equipment Co., Ltd., Viasonix, ELCAT, Atys Medical, RIMED, GE HealthCare., Siemens Healthcare GmbH, Canon Medical Systems Corporation, Hyperfine, Neural Analytics, Inc., and others.

Recent Developmental Activities in the Intracranial Pressure Monitoring Devices Market:

In December 2022, IRRAS announced that it received regulatory clearance from the US Food and Drug Administration (FDA) to activate all of the functionality on the next-generation control unit for its flagship product, IRRAflow—which it claims is the world’s first and only active fluid exchange system. IRRAflow combines automated irrigation, controlled drainage, and continuous monitoring of the patient’s intracranial pressure, into one intelligent system.

In November 2022, the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) granted approval to Invex Therapeutics to begin the Phase III IIH EVOLVE clinical trial of Presendin (sustained release (SR) Exenatide) to treat idiopathic intracranial hypertension (IIH) patients.

Key takeaways from the Intracranial Pressure Monitoring Devices market report study

Market size analysis for current intracranial pressure monitoring devices market size (2023), and market forecast for 6 years (2024 to 2030)

Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the intracranial pressure monitoring devices market

Various opportunities available for the other competitors in the intracranial pressure monitoring devices market space

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current intracranial pressure monitoring devices market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for intracranial pressure monitoring devices market growth in the coming future?

Target audience who can be benefited from this Intracranial Pressure Monitoring Devices market report study

Intracranial pressure monitoring device providers

Research organizations and consulting companies

Intracranial pressure monitoring devices related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and traders dealing in intracranial pressure monitoring devices

Various end-users who want to know more about the intracranial pressure monitoring devices market and the latest developments in the intracranial pressure monitoring devices market

Frequently Asked Questions for the Intracranial Pressure Monitoring Devices Market:

1. What are intracranial pressure monitoring devices?

The intracranial pressure monitoring devices are those devices that might be placed inside the head to monitor and sense the pressure inside the skull and then send measurements to a recording device.

2. What is the market for intracranial pressure monitoring devices?

The intracranial pressure monitoring devices market was valued at USD 1.55 billion in 2023, growing at a CAGR of 7.60% during the forecast period from 2024 to 2030 to reach USD 2.40 billion by 2030.

3. What are the drivers for the intracranial pressure monitoring devices market?

The intracranial pressure monitoring devices market is experiencing significant growth due to the increasing instances of neurological disorders such as multiple sclerosis and epilepsy, and dementia, coupled with increasing awareness of these disorders, and rising product developmental activities that are acting as major factors contributing to the overall growth of the intracranial pressure monitoring devices market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the intracranial pressure monitoring devices market?

Some of the major market players operating in the intracranial pressure monitoring devices market include ArchiMed Group, RAUMEDIC AG, Integra LifeSciences, Sophysa, Spiegelberg GmbH & Co. KG, Medtronic, IRRAS AB, Luciole Medical AG, Saeum Meditec, Recorders & Medicare Systems P Ltd., Shenzhen Delica Medical Equipment Co., Ltd., Viasonix, ELCAT, Atys Medical, RIMED, GE HealthCare., Siemens Healthcare GmbH, Canon Medical Systems Corporation, Hyperfine, Neural Analytics, Inc., and others.

5. Which region has the highest share in the intracranial pressure monitoring devices market?

Among all the regions, North America is estimated to hold a significant revenue share in the intracranial pressure monitoring devices market. This can be attributed to several factors, including the growing burden of Parkinson's disease, the increasing prevalence of brain injuries caused by trauma, and ongoing product development activities by regulatory authorities supported by the presence of key players in the region that contribute to the growth of the intracranial pressure monitoring devices market in the North America region during the forecast period from 2024 to 2030.